Entering text into the input field will update the search result below

Regulus Therapeutics misses by $0.06, beats on revenues

  • Regulus Therapeutics (NASDAQ:RGLS): Q2 EPS of -$0.20 misses by $0.06.
  • Revenue of $4.76M beats by $1.32M. (PR)

Recommended For You

More Trending News

About RGLS Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
RGLS--
Regulus Therapeutics Inc.